• MK-4827 (Niraparib): Reliable PARP-1/-2 Inhibition for Cance

  2026-06-10

  This article addresses common laboratory challenges in DNA damage repair inhibition and cell viability assays, using MK-4827 (Niraparib), a potent and selective PARP-1/-2 inhibitor (SKU A3617). Researchers will find scenario-driven guidance on protocol optimization, data interpretation, and vendor selection, all grounded in reproducible quantitative data. The piece highlights how APExBIO's MK-4827 supports robust, BRCA-focused cancer research workflows.

• Crystal Violet Staining Solution in Fungal Biofilm and Drug

  2026-06-09

  Explore how Crystal Violet Staining Solution advances nuclear staining dye protocols in studying fungal biofilm formation and antifungal resistance. This article uniquely bridges cell-based assay techniques with molecular epidemiology insights from recent C. auris research.

• Estradiol: Mechanisms, Organ Protection, and Research Applic

  2026-06-09

  Estradiol (17 beta-estradiol) is a potent estrogen that regulates gene expression via ERα and ERβ, protecting cardiovascular, renal, and metabolic health. Robust experimental and population data show that its deficiency increases risk for multimorbidity during perimenopause. APExBIO’s Estradiol is a validated tool for modeling estrogen receptor signaling and autophagy in research.

• Wortmannin: Selective PI3K Inhibitor for Advanced Research

  2026-06-08

  Wortmannin is a potent, selective, and irreversible PI3K inhibitor widely used in cancer and cell signaling research. Its nanomolar potency and high selectivity enable precise dissection of the PI3K/Akt/mTOR pathway, autophagy, and apoptosis in both in vitro and in vivo models.

• Erlotinib (NSC 718781): Applied EGFR Inhibition in Cancer Re

  2026-06-08

  Leverage Erlotinib (NSC 718781) for robust, reproducible inhibition of EGFR signaling in translational cancer research workflows. Discover validated protocol enhancements, troubleshooting insight, and how the latest SCUBE3 findings reshape advanced assay design.

• RAS/PI3K Mutations Enhance Sensitivity to PARP/NAMPT Inhibit

  2026-06-07

  The referenced study identifies RAS/PI3K pathway mutations as predictive biomarkers for enhanced sensitivity to combined PARP and NAMPT inhibition in epithelial ovarian cancer (EOC) cells. This work highlights the therapeutic potential of exploiting NAD+ metabolism in RAS/PI3K-mutant EOC and suggests new avenues for overcoming resistance to current maintenance therapies.

• Bivalent mRNA Vaccine RQ3025: Broad Protection Against SARS-

  2026-06-06

  This study introduces RQ3025, a bivalent mRNA vaccine designed to provide broad-spectrum protection against diverse SARS-CoV-2 variants. Preclinical results demonstrate robust neutralizing antibody responses and Th1-biased cellular immunity, supporting its potential for future clinical application.

• Praeruptorin A: Angular Pyranocoumarin Compound in Inflammat

  2026-06-05

  Praeruptorin A, an angular pyranocoumarin compound from Peucedanum praeruptorum, exhibits robust anti-inflammatory and anti-metastatic effects by targeting multiple signaling pathways. Its validated activity as a ferroptosis inhibitor and intestinal barrier protector is supported by quantitative in vitro and in vivo results. This article details its specific mechanisms, applications, and limitations for translational research.

• PD 0332991 (Palbociclib) HCl: Protocols and Troubleshooting

  2026-06-05

  PD 0332991 (Palbociclib) HCl empowers researchers with precise G1 phase arrest for robust antiproliferative assays in Rb-positive cancer models. This guide translates advanced mechanistic insight into stepwise protocols, troubleshooting tactics, and data-driven applications, enabling high-confidence tumor growth suppression studies.

• METTL17 Modulates Ferroptosis via Mitochondrial Translation

  2026-06-04

  This study uncovers how METTL17 regulates ferroptosis resistance in colorectal cancer by modulating mitochondrial RNA methylation and translation. The findings position METTL17 as a potential therapeutic target for sensitizing tumors to ferroptosis-based interventions.

• Erlotinib (NSC 718781): Precision EGFR Inhibition Workflows

  2026-06-04

  Erlotinib (NSC 718781) empowers researchers with nanomolar precision for dissecting EGFR-driven oncogenic signaling and resistance mechanisms in cancer models. This guide delivers actionable workflows, optimization strategies, and troubleshooting tips to maximize the translational impact of Erlotinib within advanced experimental settings.

• Rapamycin (Sirolimus): Mechanistic Precision for Translation

  2026-06-03

  Explore how Rapamycin (Sirolimus) acts as a keystone inhibitor of mTOR signaling, enabling translational researchers to dissect and modulate cellular pathways in cancer, immunology, and mitochondrial disease models. This article bridges mechanistic depth with actionable guidance, referencing new discoveries in mitophagy and differentiation, and highlights APExBIO’s validated Rapamycin for advanced experimental workflows.

• Coumestrol Induces Ferroptosis in RA-FLS via PMAIP1 Stabiliz

  2026-06-03

  This study reveals how Coumestrol, a phytoestrogen estrogen receptor antagonist, induces ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS) by stabilizing mitochondrial PMAIP1 through TRIM3 inhibition. The findings highlight a new pathway for targeting RA-FLS proliferation and inflammation, offering a promising avenue for RA intervention and selective estrogen receptor modulator studies.

• MG53 E3 Ligase Drives Cyclin D1 Degradation to Suppress Tumo

  2026-06-02

  This study uncovers MG53 as a previously unrecognized E3 ubiquitin ligase that directly targets cyclin D1 for proteasomal degradation, thereby arresting cell cycle progression and suppressing tumor growth. The findings highlight a mechanistic link between MG53 deficiency, cyclin D1 accumulation, and poor cancer outcomes, informing new strategies for targeting cyclin D1 turnover in refractory malignancies.

• Phosphotungstic Acid Negative Stain Solution (2%): Precision

  2026-06-02

  Explore how Phosphotungstic Acid Negative Stain Solution (2%) enables advanced visualization of viral glycan vulnerabilities, empowering researchers to decipher macromolecular architecture and inform antiviral strategy. This cornerstone guide delivers scientific depth and distinct workflow insights.

15853 records 3/1057 page Previous Next 12345 下5页 Last page